Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.
Biora Therapeutics Inc. (BIOR) is a clinical-stage biotechnology company pioneering smart pill-based drug delivery systems for targeted and systemic therapies. This page provides investors and stakeholders with timely updates on the company’s progress in redefining treatment for gastrointestinal diseases and chronic conditions.
Access the latest press releases, clinical trial milestones, and financial reports related to Biora’s innovative platforms—including the NaviCap™ targeted colon release system and BioJet™ needle-free delivery technology. Stay informed about regulatory developments, research collaborations, and strategic partnerships shaping the future of oral biotherapeutics.
This resource is designed for efficient tracking of BIOR’s advancements in drug-device combinations and precision medicine. Bookmark this page or check back regularly for verified updates directly from the company and trusted financial news sources.
Biora Therapeutics (Nasdaq: BIOR) announced its participation in the IBD Innovate event on April 26, 2023, in New York City. The event will center on innovative product development in inflammatory bowel disease (IBD). Biora's Head of Strategy, Chris Wahl, will present on the NaviCap™ targeted oral delivery platform, which aims to enhance outcomes for ulcerative colitis patients by delivering therapies directly to disease sites, minimizing systemic toxicity.
The NaviCap device is an ingestible medical tool designed to autonomously release therapeutic doses in the gastrointestinal tract. Biora's BT-600 program uses this device to deliver a liquid formulation of tofacitinib for ulcerative colitis. Successful studies have demonstrated the device's localization capabilities and its potential as the first non-fasting ingestible delivery system. Biora aims to submit an IND application for Phase 1 trials.
Biora Therapeutics (Nasdaq: BIOR) provided a corporate update and financial results for the fourth quarter and full year ended December 31, 2022, announcing new brand names for its delivery platforms: NaviCap™ for oral delivery and BioJet™ for systemic delivery. The company achieved a significant milestone by completing a 14-day toxicology study for its BT-600 program, reporting no adverse events. Biora also announced impressive bioavailability results in preclinical studies, surpassing its target with an average of 37% for semaglutide and 51% for adalimumab. The company raised $12.9 million through its ATM program, while operating expenses decreased from the previous year.
Biora Therapeutics (Nasdaq: BIOR) will report its fourth quarter and full year financial results for the period ending December 31, 2022, on March 30, 2023, post-market close. A webcast and conference call will follow at 4:30 PM ET to discuss the results and provide corporate updates. Biora focuses on innovative therapeutic delivery solutions, including smart pills for targeted drug delivery and needle-free biotherapeutics. The company aims to enhance patient care through advanced therapeutic options.
Biora Therapeutics (Nasdaq: BIOR) announced promising preclinical data for its PGN-OB2 program, showcasing an average bioavailability of 37% for semaglutide, significantly higher than the current oral formulation's less than 1%. Utilizing liquid jet technology in porcine models, the results suggest strong potential for oral delivery of peptides and monoclonal antibodies. This aligns with the company’s goal of exceeding a 15% bioavailability target. With broad patent protection and a commitment to advancing their systemic delivery platform, Biora plans further preclinical studies in 2023 to enhance and commercialize this innovative delivery method.
Biora Therapeutics has announced promising preliminary results from its preclinical research on the PGN-OB1 program, demonstrating an average bioavailability of 51.3% for a variant of adalimumab, a result achieved using their novel liquid jet delivery technology. This marked improvement not only surpasses previous performance metrics but also shows consistent results comparable to traditional subcutaneous administration. The study evaluated a 56 mg dose in a porcine model, with the device expected to enhance future collaborations in the pharmaceutical sector. Biora possesses a robust patent portfolio with approximately 34 patents related to its delivery methods.
